SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection.

Clin Exp Med · 2024 · PMC10827842 · PMID 38289482

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The results showed that the expression of SRRM2 in plasma cells had an increasing trend during the progression from MM to PCL (Fig. 10 C).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.